Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 12Cetuximab 9pembrolizumab 7Radiotherapy 7Fluorouracil 6Carboplatin 5Radiotherapy, Intensity-Modulated 4Nivolumab 4epacadostat 3Radiation 3Docetaxel 3Venlafaxine Hydrochloride 2Surveys and Questionnaires 2Panitumumab 2Paclitaxel 2Ketamine 2zimberelimab 1vandetanib 1tislelizumab 1temsirolimus 1ruxolitinib 1plerixafor 1nimotuzumab 1linrodostat 1fosbretabulin 1fluoromisonidazole 1fludarabine phosphate 1fludarabine 1elgemtumab 1ebselen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Head and Neck Neoplasms × linrodostat × Clear all
NCT03386838 2019-04-18

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Bristol-Myers Squibb

Phase 3 Withdrawn
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡